Xvivo Perfusion Q1: Better than expected
Sales in Q1 came in higher than expected and EBITDA beat our forecast by a margin. We are encouraged by the faster-than-expected adjustment of the cost base and strong cash flow in during the quarter. Our fair value is left unchanged.